Next Article in Journal
Osseous Union after Mandible Reconstruction with Fibula Free Flap Using Manually Bent Plates vs. Patient-Specific Implants: A Retrospective Analysis of 89 Patients
Previous Article in Journal
Framing Concerns about Body Image during Pre- and Post-Surgical Consultations for Head and Neck Cancer: A Qualitative Study of Patient–Physician Interactions
Article

Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy

1
Oncology Unit, ASL 3, Villa Scassi Hospital, Corso Scassi 1, 16149 Genoa, Italy
2
Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 12, 16100 Genoa, Italy
3
Analysis Laboratory, ASL 3, Via Bertani 4, 16125 Genoa, Italy
4
General Direction, Asl 3, Via Bertani 4, 16125 Genoa, Italy
5
Oncology Unit, Antero Micone Hospital, Largo Nevio Rosso 2, 16100 Genoa, Italy
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3364-3374; https://doi.org/10.3390/curroncol29050273
Received: 25 March 2022 / Revised: 1 May 2022 / Accepted: 3 May 2022 / Published: 6 May 2022
Background: Information on immune responses in cancer patients following mRNA COVID-19 vaccines is still insufficient, but generally, patients had impaired serological responses, especially those with hematological malignancies. We evaluated serological response to COVID-19 mRNA vaccine in cancer patients receiving chemotherapy compared with healthy controls. Methods: In total, 195 cancer patients and 400 randomly selected controls who had been administered a Pfizer-BioNTech or Moderna COVID-19 vaccines in two doses were compared. The threshold of positivity was 4.33 BAU/mL. Patients were receiving anticancer treatment after the first and second dose of the vaccines. Results: a TOTAL OF 169 patients (87%) had solid tumors and 26 hemolymphopoietic diseases. Seropositivity rate was lower in patients than controls (91% vs. 96%), with an age/gender-adjusted rate ratio (RR) of 0.95 (95% CL = 0.89–1.02). Positivity was found in 97% of solid cancers and in 50% of hemolymphopoietic tumors. Both advanced and adjuvant therapy seemed to slightly reduce seropositivity rates in patients when compared to controls (RR = 0.97, 95% CL = 0.89–1.06; RR = 0.94, 95% CL = 0.87–1.01). Conclusions: the response to vaccination is similar in patients affected by solid tumors to controls. On the contrary, hemolymphopietic patients show a much lower response than controls. View Full-Text
Keywords: COVID-19; SARS-COV-2; vaccine; cancer; anticancer treatment; seroconversion; antibodies COVID-19; SARS-COV-2; vaccine; cancer; anticancer treatment; seroconversion; antibodies
Show Figures

Figure 1

MDPI and ACS Style

Mencoboni, M.; Fontana, V.; Damiani, A.; Spitaleri, A.; Raso, A.; Bottaro, L.C.; Rossi, G.; Canobbio, L.; La Camera, A.; Filiberti, R.A.; Taveggia, P.; Cavo, A. Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy. Curr. Oncol. 2022, 29, 3364-3374. https://doi.org/10.3390/curroncol29050273

AMA Style

Mencoboni M, Fontana V, Damiani A, Spitaleri A, Raso A, Bottaro LC, Rossi G, Canobbio L, La Camera A, Filiberti RA, Taveggia P, Cavo A. Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy. Current Oncology. 2022; 29(5):3364-3374. https://doi.org/10.3390/curroncol29050273

Chicago/Turabian Style

Mencoboni, Manlio, Vincenzo Fontana, Azzurra Damiani, Antonino Spitaleri, Alessandro Raso, Luigi C. Bottaro, Giovanni Rossi, Luciano Canobbio, Antonella La Camera, Rosa A. Filiberti, Paola Taveggia, and Alessia Cavo. 2022. "Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy" Current Oncology 29, no. 5: 3364-3374. https://doi.org/10.3390/curroncol29050273

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop